Neil F. McFarlane is CEO & President at ZEVRA THERAPEUTICS, INC. (ZVRA). They have made 4 open-market trades across 2 companies since 2017, most recently 2026-10-12.
CIK 0001681098
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADMS | 600,000 | $4.9M |
| ZVRA | 417,225 | $4.1M |
| COLL | 49,365 | $1.1M |
| RTRX | 26,988 | $654K |
| Total | $10.9M |
Shares reported on the most recent Form 4, priced at the 2026-10-13 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ZVRA | SELL · 10b5-1 | 2026-10-12 | 2026-10-13 | $11.25 | $225K | — | — | — |
| ZVRA | SELL · 10b5-1 | 2026-02-09 | 2026-02-10 | $8.56 | $125K | +0.9% | +18.2% | +25.2% |
| ZVRA | SELL | 2026-02-02 | 2026-02-02 | $9.38 | $853K | -9.3% | -3.6% | +8.5% |
| ZVRA | SELL · 10b5-1 | 2025-10-10 | 2025-10-10 | $10.82 | $211K | +0.5% | -15.0% | -19.4% |
| ZVRA | SELL · 10b5-1 | 2025-02-13 | 2025-02-14 | $7.92 | $1.5M | -3.0% | +4.0% | +5.0% |
| RTRX | SELL · 10b5-1 | 2019-05-15 | 2019-05-16 | $18.25 | $36K | +2.7% | +8.2% | -5.9% |
| RTRX | SELL | 2018-12-20 | 2018-12-21 | $22.41 | $393K | +12.3% | +4.0% | +14.2% |
| RTRX | SELL | 2018-11-14 | 2018-11-16 | $23.73 | $237K | -3.4% | -9.1% | -16.7% |
| RTRX | SELL | 2017-08-16 | 2017-08-17 | $22.50 | $31K | +3.2% | -1.2% | -10.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.